Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C^–/– mice

Keyphrases

• Anemia 100%
• Ruxolitinib 100%
• Fanconi 100%
• Emergency Granulopoiesis 100%
• Wild Mice 60%
• Apoptosis 60%
• Fanconi Anemia 60%
• DNA Damage 40%
• Erythroid Progenitors 40%
• Erythropoietin 40%
• Bone Marrow Failure 40%
• Granulocytosis 40%
• Murine Model 20%
• Metabolism 20%
• Bone Marrow 20%
• Granulocytes 20%
• Acute Myeloid Leukemia 20%
• Janus Kinase 2 (JAK2) 20%
• Myeloproliferative Neoplasms 20%
• Reactive Oxygen Species 20%
• Innate Immune Response 20%
• Erythropoiesis 20%
• Steady State 20%
• Prolonged Survival 20%
• Graft-versus-host Disease (GvHD) 20%
• Autophagy Pathway 20%
• Transcriptome Analysis 20%
• DNA Repair 20%
• Inherited Disorders 20%
• Related Pathway 20%
• Granulopoiesis 20%
• Janus Kinase 1 (JAK1) 20%
• Emergency Stress 20%
• Enhanced Activity 20%
• Repeated Attempts 20%
• Hematological Manifestations 20%
• Erythropoietin Receptor 20%
• Compensatory Proliferation 20%
• Protectins 20%

Medicine and Dentistry

• Anemia 100%
• Ruxolitinib 100%
• Granulopoiesis 100%
• Programmed Cell Death 60%
• Fanconi Anemia 60%
• DNA Damage 40%
• Bone Marrow Failure 40%
• Granulocytosis 40%
• Erythropoietin 40%
• Acute Myeloid Leukemia 20%
• Innate Immunity 20%
• Steady State 20%
• Autophagy 20%
• Granulocyte 20%
• Gene Expression Profiling 20%
• Myeloproliferative Disorder 20%
• DNA Repair 20%
• Janus Kinase 2 20%
• Erythropoietin Receptor 20%
• Reactive Oxygen Species 20%
• Erythropoiesis 20%
• Graft Versus Host Reaction 20%
• Diseases 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Anemia 100%
• Ruxolitinib 100%
• Wild Type Mouse 60%
• Fanconi Anemia 60%
• Bone Marrow Depression 40%
• Granulocytosis 40%
• Erythropoietin 40%
• Reactive Oxygen Metabolite 20%
• Graft Versus Host Reaction 20%
• Myeloproliferative Disorder 20%
• Janus Kinase 2 20%
• Erythropoietin Receptor 20%
• Transcriptome 20%
• Acute Myeloid Leukemia 20%
• Diseases 20%